Skip to main content

Advertisement

SpringerLink
Log in

Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists

  • Special Section: Neuroendocrine Neoplasms
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Pancreatic neuroendocrine neoplasms (PaNENs) are a unique group of pancreatic neoplasms with a wide range of clinical presentations and behaviors. Given their heterogeneous appearance and increasing detection on cross-sectional imaging, it is essential that radiologists understand the variable presentation and distinctions PaNENs display compared to other pancreatic neoplasms. Additionally, some of these neoplasms may be hormonally functional, and it is imperative that radiologists be aware of the common clinical presentations of hormonally active PaNENs. Knowledge of PaNEN pathology and treatments may influence which imaging modality is optimal for each patient. Each imaging modality used for PaNENs has distinct advantages and disadvantages, particularly in different treatment settings. Thus, the focus of this manuscript is to provide an update for the radiologist on PaNEN pathology, imaging, and treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Li X, Gou S, Liu Z, Ye Z, Wang C. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis. Cancer Med. 2018;7(3):626–34. doi: https://doi.org/10.1002/cam4.1336.

  2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335–42. doi: https://doi.org/10.1001/jamaoncol.2017.0589.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lu L, Shang Y, Mullins CS, Zhang X, Linnebacher M. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncol. 2021;17(5):549–63. doi: https://doi.org/10.2217/fon-2020-0543.

    Article  CAS  PubMed  Google Scholar 

  4. Khanna L, Prasad SR, Sunnapwar A, Kondapaneni S, Dasyam A, Tammisetti VS, et al. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification. Radiographics. 2020;40(5):1240–62. doi: https://doi.org/10.1148/rg.2020200025.

    Article  PubMed  Google Scholar 

  5. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18, vii. doi: https://doi.org/10.1016/j.ecl.2010.12.005.

  6. Owens R, Gilmore E, Bingham V, Cardwell C, McBride H, McQuaid S, et al. Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis. Histopathology. 2020;77(4):646–58. doi: https://doi.org/10.1111/his.14200.

    Article  PubMed  Google Scholar 

  7. Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86. doi: https://doi.org/10.1038/s41379-018-0110-y.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47(3):463–70. doi: https://doi.org/10.1016/j.ecl.2018.04.008.

    Article  PubMed  Google Scholar 

  9. Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21(10):1191–9. doi: https://doi.org/10.1634/theoncologist.2015-0476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64. doi: https://doi.org/10.1530/ERC-15-0119.

    Article  CAS  PubMed  Google Scholar 

  11. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991–1002. doi: https://doi.org/10.1016/j.neo.2017.09.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. The American Journal of Surgical Pathology. 2011;35(6):853–60.

    Article  PubMed  Google Scholar 

  13. Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017;24(7):R261–R74. doi: https://doi.org/10.1530/erc-16-0538.

    Article  CAS  PubMed  Google Scholar 

  14. Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656–69. doi: https://doi.org/10.1038/s41574-018-0082-5.

    Article  CAS  PubMed  Google Scholar 

  15. National Comprehensive Cancer Network: Neuroendocrine and Adrenal Tumors (Version 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Accessed October 5, 2020.

  16. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49(7):863–81. doi: https://doi.org/10.1097/MPA.0000000000001597.

    Article  PubMed  Google Scholar 

  17. Kim JH, Eun HW, Kim YJ, Lee JM, Han JK, Choi BI. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur Radiol. 2016;26(5):1338–47. doi: https://doi.org/10.1007/s00330-015-3941-7.

    Article  PubMed  Google Scholar 

  18. Singh A, Hines JJ, Friedman B. Multimodality Imaging of the Pancreatic Neuroendocrine Tumors. Semin Ultrasound CT MR. 2019;40(6):469–82. doi: https://doi.org/10.1053/j.sult.2019.04.005.

    Article  PubMed  Google Scholar 

  19. Yano M, Misra S, Salter A, Carpenter DH. Assessment of disease aggression in cystic pancreatic neuroendocrine tumors: A CT and pathology correlation study. Pancreatology. 2017;17(4):605–10. doi: https://doi.org/10.1016/j.pan.2017.05.388.

    Article  PubMed  Google Scholar 

  20. Verde F, Fishman EK. Calcified pancreatic and peripancreatic neoplasms: spectrum of pathologies. Abdom Radiol (NY). 2017;42(11):2686–97. doi: https://doi.org/10.1007/s00261-017-1182-8.

    Article  PubMed  Google Scholar 

  21. Nanno Y, Matsumoto I, Zen Y, Otani K, Uemura J, Toyama H, et al. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann Surg Oncol. 2017;24(4):1127–33. doi: https://doi.org/10.1245/s10434-016-5663-8.

    Article  PubMed  Google Scholar 

  22. Park HJ, Kim HJ, Kim KW, Kim SY, Choi SH, You MW, et al. Comparison between neuroendocrine carcinomas and well-differentiated neuroendocrine tumors of the pancreas using dynamic enhanced CT. Eur Radiol. 2020;30(9):4772–82. doi: https://doi.org/10.1007/s00330-020-06867-w.

    Article  PubMed  Google Scholar 

  23. De Robertis R, Paiella S, Cardobi N, Landoni L, Tinazzi Martini P, Ortolani S, et al. Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay. Abdom Radiol (NY). 2018;43(3):613–9. doi: https://doi.org/10.1007/s00261-017-1243-z.

    Article  Google Scholar 

  24. Lin XZ, Wu ZY, Tao R, Guo Y, Li JY, Zhang J, et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol. 2012;81(10):2487–94. doi: https://doi.org/10.1016/j.ejrad.2011.10.028.

    Article  PubMed  Google Scholar 

  25. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology. 2017;105(3):212–44. doi: https://doi.org/10.1159/000471879.

    Article  CAS  PubMed  Google Scholar 

  26. Lo GC, Kambadakone A. MR Imaging of Pancreatic Neuroendocrine Tumors. Magn Reson Imaging Clin N Am. 2018;26(3):391–403. doi: https://doi.org/10.1016/j.mric.2018.03.010.

    Article  PubMed  Google Scholar 

  27. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49(1):1–33. doi: https://doi.org/10.1097/mpa.0000000000001454.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc. 2011;73(4):691–6. doi: https://doi.org/10.1016/j.gie.2010.08.030.

    Article  PubMed  Google Scholar 

  29. Ronot M, Cuccioli F, Dioguardi Burgio M, Vullierme MP, Hentic O, Ruszniewski P, et al. Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. European Journal of Radiology. 2017;89:156–62. doi: https://doi.org/10.1016/j.ejrad.2017.02.007.

    Article  PubMed  Google Scholar 

  30. Cui Y, Li ZW, Li XT, Gao SY, Li Y, Li J, et al. Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma. Oncotarget. 2017;8(64):108146–55. doi: https://doi.org/10.18632/oncotarget.22554.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bhayana R, Baliyan V, Kordbacheh H, Kambadakone A. Hepatobiliary phase enhancement of liver metastases on gadoxetic acid MRI: assessment of frequency and patterns. Eur Radiol. 2020. doi: https://doi.org/10.1007/s00330-020-07228-3.

    Article  PubMed  Google Scholar 

  32. Kulali F, Semiz-Oysu A, Demir M, Segmen-Yilmaz M, Bukte Y. Role of diffusion-weighted MR imaging in predicting the grade of nonfunctional pancreatic neuroendocrine tumors. Diagnostic and Interventional Imaging. 2018;99(5):301–9.

    Article  CAS  PubMed  Google Scholar 

  33. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, et al. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). 2020. doi: https://doi.org/10.1007/s00261-020-02833-8.

    Article  PubMed  Google Scholar 

  34. Marion-Audibert A-M, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology. 2003;125(4):1094–104.

    Article  PubMed  Google Scholar 

  35. Rodallec M, Vilgrain V, Couvelard A, Rufat P, O’Toole D, Barrau V, et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology. 2006;6(1–2):77–85.

    Article  CAS  PubMed  Google Scholar 

  36. Sallinen V, Haglund C, Seppänen H. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter? Surgery. 2015;158(6):1556–63. doi: https://doi.org/10.1016/j.surg.2015.04.035.

    Article  PubMed  Google Scholar 

  37. McGovern JM, Singhi AD, Borhani AA, Furlan A, McGrath KM, Zeh HJ, 3rd, et al. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2018;211(5):1020–5. doi: https://doi.org/10.2214/AJR.17.19490.

    Article  PubMed  Google Scholar 

  38. Guo C-g, Ren S, Chen X, Wang Q-d, Xiao W-b, Zhang J-f, et al. Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. Cancer Management and Research. 2019;11:1933.

  39. Zhu JK, Wu D, Xu JW, Huang X, Jiang YY, Edil BH, et al. Cystic pancreatic neuroendocrine tumors: A distinctive subgroup with indolent biological behavior? A systematic review and meta-analysis. Pancreatology. 2019;19(5):738–50. doi: https://doi.org/10.1016/j.pan.2019.05.462.

    Article  PubMed  Google Scholar 

  40. Lee H, Eads JR, Pryma DA. (68) Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors. Oncologist. 2021;26(1):21–9. doi: https://doi.org/10.1634/theoncologist.2020-0165.

    Article  CAS  PubMed  Google Scholar 

  41. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med. 2019;60(7):937–43. doi: https://doi.org/10.2967/jnumed.118.230607.

    Article  CAS  PubMed  Google Scholar 

  42. Basu B, Basu S. Correlating and combining genomic and proteomic assessment with in vivo molecular functional imaging: Will this be the future roadmap for personalized cancer management? : Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2016.

  43. Galgano S, Viets Z, Fowler K, Gore L, Thomas JV, McNamara M, et al. Practical Considerations for Clinical PET/MR Imaging. PET Clin. 2018;13(1):97–112. doi: https://doi.org/10.1016/j.cpet.2017.09.002.

    Article  PubMed  Google Scholar 

  44. Galgano SJ, Calderone CE, Xie C, Smith EN, Porter KK, McConathy JE. Applications of PET/MRI in Abdominopelvic Oncology. Radiographics. 2021;41(6):1750–65. doi: https://doi.org/10.1148/rg.2021210035.

    Article  PubMed  Google Scholar 

  45. Galgano SJ, Wei B, Rose JB. PET Imaging of Neuroendocrine Tumors. Radiol Clin North Am. 2021;59(5):789–99. doi: https://doi.org/10.1016/j.rcl.2021.05.006.

    Article  PubMed  Google Scholar 

  46. Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ. CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. Radiographics. 2017;37(5):1483–503. doi: https://doi.org/10.1148/rg.2017170056.

    Article  PubMed  Google Scholar 

  47. Choi TW, Kim JH, Yu MH, Park SJ, Han JK. Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis. Acta Radiologica. 2018;59(4):383–92.

    Article  CAS  PubMed  Google Scholar 

  48. Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of pancreatic neuroendocrine tumor grade based on CT features and texture analysis. American Journal of Roentgenology. 2018;210(2):341–6.

    Article  PubMed  Google Scholar 

  49. van Riet PA, Larghi A, Attili F, Rindi G, Nguyen NQ, Ruszkiewicz A, et al. A multicenter randomized trial comparing a 25-gauge EUS fine-needle aspiration device with a 20-gauge EUS fine-needle biopsy device. Gastrointest Endosc. 2019;89(2):329–39. doi: https://doi.org/10.1016/j.gie.2018.10.026.

    Article  PubMed  Google Scholar 

  50. AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.

  51. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120–34. doi: https://doi.org/10.1159/000335587.

    Article  CAS  PubMed  Google Scholar 

  52. Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am. 2019;99(4):793–814. doi: https://doi.org/10.1016/j.suc.2019.04.014.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol. 2019;35(5):468–77. doi: https://doi.org/10.1097/mog.0000000000000571.

    Article  CAS  PubMed  Google Scholar 

  54. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. doi: https://doi.org/10.1097/MPA.0b013e31828e34a4.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Mittra ES. Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE. AJR Am J Roentgenol. 2018;211(2):278–85. doi: https://doi.org/10.2214/ajr.18.19953.

    Article  PubMed  Google Scholar 

  56. D'Souza D, Golzarian J, Young S. Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions. Curr Treat Options Oncol. 2020;21(6):52. doi: https://doi.org/10.1007/s11864-020-00751-x.

    Article  PubMed  Google Scholar 

  57. Galgano SJ, Iravani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2022. doi: https://doi.org/10.2214/ajr.21.27159.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

    Samuel J. Galgano & Kedar Sharbidre

  2. Department of Radiology, M.D. Anderson Cancer Center, Houston, TX, USA

    Ajaykumar C. Morani, Sanaz Javadi, Silvana Faria & Priya Bhosale

  3. Department of Radiology, University of Florida-Jacksonville, Jacksonville, FL, USA

    Dheeraj R. Gopireddy & Chandana Lall

  4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    David D. B. Bates

  5. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    Ajit H. Goenka

  6. Department of Radiology, University of Arizona-Tuscon, Tuscon, AZ, USA

    Hina Arif-Tiwari

  7. Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA

    Malak Itani & Amir Iravani

  8. Department of Medicine, University of California San Francisco, San Francisco, CA, USA

    Emily Bergsland

  9. Department of Radiology, University of Cincinnati, Cincinnati, OH, USA

    Sadhna Verma

  10. Department of Radiology, Michigan Medicine, Ann Arbor, MI, USA

    Isaac R. Francis

  11. Department of Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA

    Daniel M. Halperin

  12. Department of Pathology, M.D. Anderson Cancer Center, Houston, TX, USA

    Deyali Chatterjee

  13. Department of Radiology, Mayo Clinic Arizona, Scottsdale, AZ, USA

    Motoyo Yano

Authors
  1. Samuel J. Galgano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajaykumar C. Morani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dheeraj R. Gopireddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kedar Sharbidre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David D. B. Bates
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ajit H. Goenka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hina Arif-Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Malak Itani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Amir Iravani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sanaz Javadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Silvana Faria
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chandana Lall
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emily Bergsland
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Sadhna Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Isaac R. Francis
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Daniel M. Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Deyali Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Priya Bhosale
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Motoyo Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel J. Galgano.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Galgano, S.J., Morani, A.C., Gopireddy, D.R. et al. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol 47, 3962–3970 (2022). https://doi.org/10.1007/s00261-022-03466-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-022-03466-9

Keywords

Search

Navigation